Olanzapine for delirium in parkinsonism: Therapeutic benefits in lieu of adverse consequences [6]

Neurology India

Volumn 52, Issue 2, 2004, Pages 274-275

  Gupta, N ^a   Sharma, Parveen ^a   Prabhakar, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; IMIPRAMINE; OLANZAPINE; RISPERIDONE; TRIHEXYPHENIDYL; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; DELIRIUM; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDROCEPHALUS; LETTER; LOW DRUG DOSE; MUSCLE RIGIDITY; PARKINSONISM; PSYCHOLOGICAL ASPECT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELIRIUM; FEMALE; HUMANS; PARKINSONIAN DISORDERS;

EID: 4344669883     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Wolters ECh. Dopaminomimetic psychosis in parkinson's disease patients: Diagnosis and treatment. Neurology 1999;52:S10-13.
2. Lishman WA. Organic Psychiatry: The psychological consequences of cerebral disorder 3rd (Ed). Blackwell Science. Oxford 1998.
3. Sadock BJ, Sadock VA. Comprehensive Textbook of Psychiatry, 7th (Ed). Philadelphia: Lippincott Williams & Wilkins 2000.
4. Trzepacz PT. Delirium: Advances in diagnosis, pathophysiology and treatment. Psychiatr Clin North Am 1996;19:429-48.
5. Juncos JL. Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1000;60:42-53.
6. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998;50:1195-6.
7. Weiner WJ, Minager A, Shulman LM. Quetiapine for L-dopa-induced psychosis in PD. Neurology 2000;54:1538.